QTX-2101, an oral arsenic trioxide, received FDA fast track designation for acute promyelocytic leukemia, aiming to simplify ...

Quetzal Therapeutics, a biopharmaceutical company focused on developing treatments for rare diseases, announced that the U.S.

The Food and Drug Administration (FDA) has granted Fast Track designation to QTX-2101, an oral formulation of arsenic trioxide, for the treatment of acute promyelocytic leukemia (APL), an aggressive ...

CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics , a biopharmaceutical company specializing in developing transformative treatments for rare diseases, announced the initiation of a ...

Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have invented an oral formulation of arsenic trioxide (Oral-ATO; ARSENOL) for the treatment of acute promyelocytic ...

Acute promyelocytic leukaemia (APL) represents a unique and once highly fatal subtype of acute myeloid leukaemia that is now considered among the most curable forms of haematological malignancies.

Researchers at Zhejiang University School of Medicine have identified a single point mutation in the normal PML gene that can block the effect of arsenic trioxide, a frontline drug for acute ...

A case study published by researchers at Johns Hopkins University showed that optical genome mapping (OGM) detected a structural variant that was missed by karyotyping and non-informative by FISH, ...

Findings from the international study involving about 220 newly diagnosed and relapse patient samples pave the way for development of new therapies A study led by a team of scientists from the Cancer ...